MEX BIO
News
FEDERAL GOVERNMENT
SUPPORT FOR BIOTECHNOLOGY
1. INVESTMENT AND CAPITAL ATTRACTION
- Tax Incentives Decree under Plan México (January 21, 2025). Mexico is promoting new investments in biotechnology, pharmaceuticals, and advanced manufacturing through immediate investment deductions, incentives for technological innovation, and the strengthening of industrial capabilities focused on the development of biotechnological medicines and biosimilars.
DOF, 21-01-2025.https://www.dof.gob.mx/nota_detalle_popup.php?codigo=5747410&utm_source
Decree for the Immediate Authorization of Investments (May 4, 2026). The Federal Government prioritizes strategic sectors such as biopharmaceuticals, biotechnology, medical devices, and biotechnological medicines through administrative simplification, digitalization, and reduced regulatory timelines to attract national and international investment.
DOF, 04-05-2026.
https://sidof.segob.gob.mx/notas/5786597?utm_sourceTax Incentives Decree for Economic Development Poles for Wellbeing (May 22, 2025). Mexico is strengthening industrial and technological development hubs to attract investment in biotechnology, biosimilars, and high-impact pharmaceutical value chains, promoting regional development and industrial innovation.
DOF, 22-05-2025.
https://sidof.segob.gob.mx/notas/5758077?utm_sourc
2. TECHNOLOGICAL DEVELOPMENT AND INNOVATION
- Sectoral Program for Science, Humanities, Technology, and Innovation 2025–2030 (SECIHTI). SECIHTI’s national strategy strengthens technological sovereignty, applied research, and industry-academia collaboration to accelerate the development of biotechnology, biopharmaceuticals, biosimilars, and health innovation platforms.
DOF, 17-09-2025.
https://sidof.segob.gob.mx/notas/5767977?utm_source
3. TAX INCENTIVES
- Guidelines for the Plan México Tax Incentives Decree (March 21, 2025). The Federal Government establishes operational mechanisms to facilitate access to tax incentives aimed at innovation projects, biotechnology, technology transfer, and the development of biotechnological medicines and biosimilars.
DOF, 21-03-2025.
https://sidofqa.segob.gob.mx/notas/5752575?utm_source
4. QUALITY REGULATORY FRAMEWORK FOR BIOTECHNOLOGICAL PRODUCTS
- Good Manufacturing Practices (GMP) Guidelines for Medicines and Biotechnological Products (March 20, 2025). Mexico is strengthening international regulatory standards for biotechnological medicines and biosimilars through GMP guidelines aimed at improving quality, manufacturing, and international competitiveness.
DOF, 20-03-2025.
https://sidof.segob.gob.mx/notas/5752433?utm_source - Guidelines for Abbreviated Regulatory Pathways for Health Registrations (July 18, 2025). The new regulatory framework accelerates access to biotechnological medicines, biosimilars, and health technologies through the recognition of international regulatory agencies and abbreviated procedures.
DOF, 18-07-2025.
https://sidof.segob.gob.mx/notas/5763319?utm_source
5. INDUSTRIAL PROPERTY
- IMPI–COFEPRIS Collaboration Agreement (March 6, 2025). Mexico is strengthening the regulatory and industrial property ecosystem to protect innovation in biotechnology, biotechnological medicines, and biosimilars through strategic coordination between health regulation and patent protection.
DOF, 06-03-2025.
https://sidof.segob.gob.mx/notas/5751072?utm_source Regulations of the Federal Law for the Protection of Industrial Property (April 28, 2026). The modernization of the industrial property system strengthens the protection of biotechnology patents, technology transfer, and commercialization of innovation related to biotechnological medicines, biosimilars, and health technologies.
DOF, 28-04-2026.
https://sidof.segob.gob.mx/notas/5786237?utm_source